Transforming mental health through digital diagnosis

At Psyomics, we are transforming the way mental health concerns are identified and stratified, paving the way for better understanding, treatment and outcomes.

Maximise clinical capacity while improving patient experience

We believe that the key to improving mental health treatment and outcomes comes from gaining a better understanding of an individual’s mental health challenges and needs from the beginning.

Psyomics is developing software to support healthcare practitioners by providing a more comprehensive picture of a patient’s mental wellbeing. Co-developed by psychiatrists and built on evidence-based mental health research, our digital diagnostic tools can be used to efficiently assess and triage patients at all levels, in both NHS and private mental healthcare settings.

By using technology to enable effective and consistent diagnosis, we aim to maximise clinical efficiency, support effective treatment and facilitate successful triaging.

Primary care practitioners are seeing increasing numbers of patients with mental health concerns and needs. Mental health technology innovations are crucial to relieve the pressure on services, increase clinical efficiencies and provide a stronger base for improvements within treatment.

Censeo - mirroring the psychiatric assessment process

Our extensive research has led to the development of our primary software and platform called Censeo.

Censeo is a unique digital diagnostic platform that combines technology with clinical expertise to mirror a full psychiatric assessment. Sophisticated algorithms guide the patient through a series of adaptive questions to build a complete understanding of their mental health.

A detailed diagnostic report, signed off by a practising psychiatrist, provides key information to support clinicians with efficient triaging and treatment planning. Extensive, patient-focused psychoeducation and additional sources of help are included to improve patient understanding and improve self-management of symptoms.

Censeo supports primary care practitioners by sensitively redirecting non-clinical presentations, supporting treatment with a psychiatrist-approved treatment plan and making it easier to refer on to the most appropriate service.

Find Out More
Find Out More

Research

Research is a fundamental part of our business. Everything we do is supported by in-depth scientific and clinical research. We are committed to transforming mental health diagnosis and producing clinically validated digital solutions for mental healthcare. 

Psyomics was co-founded by Professor Sabine Bahn, head of the Cambridge Centre for Neuropsychiatric Research (CCNR). Based at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, CCNR coordinates and carries out fundamental and applied research into the causes and treatment of major neuropsychiatric disorders. CCNR has a particular focus on bipolar and major depressive disorder.

Psyomics developed a comprehensive digital assessment platform to be used as part of a large-scale clinical trial called the Delta Trial. This was conducted by CCNR to improve the detection of bipolar disorder and depression.

Find Out More

About Us

Psyomics develops unique technology to radically improve the way mental health conditions are assessed and triaged. Drawing on both psychiatric and psychological expertise, our digital diagnostic devices provide every patient direct access to a complete mental health review at the first point of contact.

Our aim is to revolutionise the way mental health conditions are identified and diagnosed, increasing clinical capacity and helping patients to access the right level of support, first time, every time.

Psyomics was co-founded by Professor Sabine Bahn, head of the Cambridge Centre for Neuropsychiatric Research (CCNR) and Daniel Cowell, former COO of Horizon Discovery, with the goal of improving diagnosis of neuropsychiatric disorders. The company is supported by Cambridge Enterprise, Innovate UK, Parkwalk and European Commission’s Horizon 2020 programme.

Find Out More

Quality and regulatory standards

Psyomics is dedicated to maintaining the highest levels of quality management throughout our whole business and at every stage of product development. We are committed to delivering outstanding products and services that not only comply with all the required regulations and standards, but exceed them.

Censeo is a registered Class I Medical Device, meaning our products meet the required standards for patient care and safety. 

Find Out More

News & Articles

Show All
Contact
Contact address

Psyomics Ltd

Innovation Centre

320 Cambridge Science Park

Milton Rd

Cambridge

CB4 0WG

United Kingdom

Cambridge Innovation Centre, 320 Cambridge Science Park Milton Road, Cambridge, CB4 0WG
PsyOmics Ltd is registered in England and Wales (Registered number: 09470381)
Registered Office: Beech House, 4a Newmarket Road, Cambridge, CB5 8DT
VAT Registration No. 233 2946 14